Phase 1 Thyroid Cancer Trial, Recruiting NCT07244835 Sponsor: Degron Therapeutics Co. Condition: Thyroid Cancer
Back to Thyroid Cancer

Phase 1 Thyroid Cancer Trial, Recruiting

NCT07244835
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a consent form agreeing to take part in the study
  • You are 18 years of age or older
  • If you are a woman who could become pregnant, you must agree to use highly effective birth control during the study and for 30 days after your last dose, and must have 2 negative pregnancy tests before starting (at least one must be a blood test)
  • If you are a woman who cannot become pregnant, this applies if you have been through menopause or have had a surgical procedure to prevent pregnancy
  • If you are a man, you must agree to ensure your female partner uses highly effective birth control during the study and for at least 30 days after your last dose, and you must not donate sperm during this time
  • You have an advanced solid tumour cancer that has not responded to standard treatments, or no standard treatment is available for your cancer
  • In Part 1 of the study, any type of advanced solid tumour is eligible; in Part 2, your tumour must have a specific gene change called a BRAF mutation, or you must have liver cancer (HCC)
  • You have at least one tumour that can be measured using standard imaging scans
  • You are generally well enough to carry out light daily activities (this is measured using a standard scale called ECOG, with a score of 0 or 1)

Who may not be able to join:

  • You have a serious medical condition, abnormal lab results, or a mental health condition that could make it unsafe for you to participate
  • You have a condition that could make it difficult for doctors to understand the results of the study
  • You are currently pregnant or breastfeeding
  • You have received treatment for another cancer (including chemotherapy, radiation, or antibody therapy) within a recent short period before starting this study (confirm with trial site for exact timeframes)
  • You have brain metastases (cancer that has spread to the brain) that are causing symptoms, are unstable, or require treatment such as steroids that have recently been increased
  • You have a significant heart or blood vessel condition
  • You have an active infection that requires ongoing medication within 2 weeks of starting the study
  • You have HIV, AIDS, or an active hepatitis B or hepatitis C infection

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-21-60799565

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Degron Therapeutics Co.
Registry
ClinicalTrials.gov
Start date
13 November 2025
Est. completion
1 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of dose limiting toxicity (DLT); Incidence of adverse events (AEs) and serious AEs (SAEs) as assessed by CTCAE v5.0

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov